CN Patent

CN113582924A — 一种多靶点酪氨酸激酶抑制剂及其制备方法和用途

Assigned to Sichuan Guokang Pharmaceutical Co Ltd · Expires 2021-11-02 · 5y expired

What this patent protects

本发明提供了式I所示化合物或其药学上可接受的盐，可抑制多种酪氨酸激酶，对VEGFR1、VEGFR2、VEGFR3、FGFR1、FGFR 2、FGFR 3、FGFR 4、PDGFRα、KIT和RET等均具有抑制作用，作为多靶点酪氨酸激酶抑制剂使用，在预防和/或治疗与酪氨酸激酶过表达相关的肿瘤治疗中具有潜在的应用前景。

USPTO Abstract

本发明提供了式I所示化合物或其药学上可接受的盐，可抑制多种酪氨酸激酶，对VEGFR1、VEGFR2、VEGFR3、FGFR1、FGFR 2、FGFR 3、FGFR 4、PDGFRα、KIT和RET等均具有抑制作用，作为多靶点酪氨酸激酶抑制剂使用，在预防和/或治疗与酪氨酸激酶过表达相关的肿瘤治疗中具有潜在的应用前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN113582924A
Jurisdiction
CN
Classification
—
Expires
2021-11-02
Drug substance claim
No
Drug product claim
No
Assignee
Sichuan Guokang Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.